Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 242Lung Neoplasms 59Neoplasms 57Head and Neck Neoplasms 57Stomach Neoplasms 56Squamous Cell Carcinoma of Head and Neck 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasm Metastasis 40Small Cell Lung Carcinoma 38Urinary Bladder Neoplasms 28Uterine Cervical Neoplasms 26Esophageal Neoplasms 25Colorectal Neoplasms 24Cholangiocarcinoma 24Biliary Tract Neoplasms 24Carcinoma 23Ovarian Neoplasms 21Carcinoma, Transitional Cell 18Carcinoma, Squamous Cell 17Recurrence 16Esophageal Squamous Cell Carcinoma 16Melanoma 13Breast Neoplasms 13Non-Squamous Non-Small Cell Lung Cancer 12Mesothelioma, Malignant 12Mesothelioma 12Nasopharyngeal Carcinoma 11Endometrial Neoplasms 11Adenocarcinoma 11Gallbladder Neoplasms 10

Interventions

Trastuzumab 3Oxaliplatin 3Capecitabine 3trastuzumab deruxtecan 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1Ramucirumab 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × HER2-positive Gastric Cancer × Cisplatin × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡